Cost and effectiveness of hepatitis C virus cryoglobulinemia vasculitis (HCV-CryoVas) treatment in the era of direct acting antivirals (DAA) in a tertiary French center

被引：0
|
作者：
Cacoub, Patrice P. [1 ,2 ]
Vautier, Mathieu [1 ,2 ]
Desbois, Anne Claire [1 ,2 ]
Doz, Marianne [3 ]
Lafuma, Antoine [3 ]
机构：
[1] Grp Hosp Pitie Salpetriere, AP HP, Dept Internal Med & Clin Immunol, Paris, France
[2] Univ Paris 06, Sorbonne Univ, UMR 7211, Inflammat Immunopathol Biotherapy Dept DHU I2B, Paris, France
[3] CEMKA, Paris, France
来源：
HEPATOLOGY | 2016年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
817
引用
收藏
页码：402A / 402A
页数：1
相关论文
共 50 条
  • [1] Sofosbuvir plus daclatasvir for hepatitis C virus-cryoglobulinemia vasculitis (HCV-CryoVas): VASCUVALDIC 2 Study
    Saadoun, D.
    Pol, S.
    Ferfar, Y.
    Hezode, C.
    Ahmed, S. N. S.
    Alric, L.
    de Saint Martin, L.
    Bouyer, A. S.
    Musset, L.
    Poynard, T.
    Rigon, M. R.
    Cacoub, P.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S56 - S57
  • [2] Treatment of chronic hepatitis C-associated cryoglobulinemia vasculitis at the era of direct-acting antivirals
    Comarmond, Cloe
    Cacoub, Patrice
    Saadoun, David
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2020, 13
  • [3] Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon-based to direct-acting antivirals era
    Cacoub, Patrice
    Vautier, Mathieu
    Desbois, Anne Claire
    Lafuma, Antoine
    Saadoun, David
    LIVER INTERNATIONAL, 2017, 37 (12) : 1805 - 1813
  • [4] COST-EFFECTIVENESS OF DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C VIRUS IN RUSSIA
    Ignatyeva, V
    Pyadushkina, E.
    Derkach, E., V
    VALUE IN HEALTH, 2019, 22 : S646 - S647
  • [5] Treatment of HCV in the Department of Corrections (DOC) in the era of Oral Direct Acting Antivirals (DAA)
    Sterling, Richard K.
    Cherian, Reena
    Shawn, Lewis
    Chhatrala, Ravi
    Alsaleh, Anas
    Genther, Kathleen
    Driscoll, Carloyn
    Martin, Kelly
    Matherly, Scott C.
    Siddiqui, Mohammad
    Luketic, Velimir A.
    Stravitz, R. Todd
    Puri, Puneet
    Lee, Hannah
    Smith, Paula G.
    Sanyal, Arun J.
    HEPATOLOGY, 2016, 64 : 438A - 439A
  • [6] Ribavirin in the New Era of Direct-acting Antivirals (DAA) for Hepatitis C Virus (HCV): How Low Is Low Dose Ribavirin?
    Dutta, Sangitanjan
    Talukdar, Anjan Jyoti
    Tiwari, Avinash
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S1496 - S1497
  • [7] IMPACT OF HEPATITIS C VIRUS (HCV) ERADICATION FOLLOWING DIRECT ACTING ANTIVIRALS TREATMENT (DAA) ON LIVER STIFFNESS MEASUREMENT (LSM)
    Khalil, Mohammed Tag-Adeen S.
    Sapra, Ahlam M.
    Akazawa, Yuko
    Ohnita, Ken
    Nakao, Kazuhiko
    GASTROENTEROLOGY, 2017, 152 (05) : S1105 - S1106
  • [8] Cost effectiveness of direct acting antivirals in the treatment of hepatitis C in vulnerable populations
    Verma, Dhruv
    Ashkar, Carina
    Saab, Sammy
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (01) : 9 - 12
  • [9] Direct-Acting Antivirals (DAAs) treatment Improves Hepatitis C Virus (HCV)-Associated Mixed Cryoglobulinemia Symptoms.
    Pollastri, Ester
    Spinetti, Angiola
    Odolini, Silvia
    Tomasoni, Lina
    Lanza, Paola A.
    Bonito, Andrea
    Zaltron, Serena
    Nasta, Paola
    Urbinati, Lucia
    Biasi, Luciano
    Festa, Elena
    Casari, Salvatore
    Affatato, Stefania
    Belotti, Elena
    Zani, Roberta
    Scaini, Patrizia
    Cancarini, Giovanni
    Castelli, Francesco
    HEPATOLOGY, 2017, 66 : 820A - 820A
  • [10] Outcomes of Antiviral Treatment (AVT) in Hepatitis C Virus (HCV) Liver Transplant (LT) Patients off Immunosuppression (IS) in Direct Acting Antivirals (DAA) Era.
    Agudelo, E.
    Campos-Varela, I.
    Terrault, N.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 972 - 972
12345